Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC)

NCT07354061 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

NSCLC (Non-small Cell Lung Cancer)

Interventions

DRUG: Ensartinib + Chemotherapy

Sponsor

Tang-Du Hospital